Advertisement

erb-B2 as a Therapeutic Target

  • Robert Mass
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Trastuzumab is a humanized monoclonal antibody that targets the type 1 tyrosine kinase receptor erb-B2 and has demonstrated survival benefit when used in combination with chemotherapy in the treatment of metastatic, HER2 overexpressing breast cancer. This chapter reviews the history of the development of trastuzumab including the biology of HER signaling, the technical issues of antibody “humanization,” the diagnostic challenges in developing “targeted” therapeutic agents, and the clinical data that led to the approval of this agent for patients with HER2 overexpressing breast cancer.

Key Words

Breast cancer HER2 erb-B2 trastuzumab monoclonal antibody targeted therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–137.PubMedCrossRefGoogle Scholar
  2. 2.
    Pinkas-Kramarski R, et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452–2467.PubMedGoogle Scholar
  3. 3.
    Ogiso H, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002;1 10:775–787.CrossRefGoogle Scholar
  4. 4.
    Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002;297:1330–1333.PubMedCrossRefGoogle Scholar
  5. 5.
    Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756–760.PubMedCrossRefGoogle Scholar
  6. 6.
    DiFiore PP, et al. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178–182.CrossRefGoogle Scholar
  7. 7.
    Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of HIB3T3 cells. PNAS 1987;84:7159–7163.PubMedCrossRefGoogle Scholar
  8. 8.
    Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132–1139.PubMedCrossRefGoogle Scholar
  9. 9.
    Slamon DJ, Clark G, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.PubMedCrossRefGoogle Scholar
  10. 10.
    Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;7:1049–1056.Google Scholar
  11. 11.
    Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998;16:1340–1349.PubMedGoogle Scholar
  12. 12.
    Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960–4970.PubMedGoogle Scholar
  13. 13.
    Press MF, Bernstein L, Thomas PA, et al. HER-2/neu amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894–2904.PubMedGoogle Scholar
  14. 14.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.PubMedCrossRefGoogle Scholar
  15. 15.
    Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550–1558.PubMedGoogle Scholar
  16. 16.
    Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117–127.PubMedCrossRefGoogle Scholar
  17. 17.
    Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255–263.PubMedCrossRefGoogle Scholar
  18. 18.
    Carter P, Presta L, et al. Humanization of an anti-p185 antibody for human cancer therapy. PNAS 1992;89:4285–4289.PubMedCrossRefGoogle Scholar
  19. 19.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829–1838.PubMedGoogle Scholar
  20. 20.
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–744.PubMedGoogle Scholar
  21. 21.
    Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.PubMedGoogle Scholar
  22. 22.
    Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.PubMedCrossRefGoogle Scholar
  23. 23.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.PubMedCrossRefGoogle Scholar
  24. 24.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.PubMedGoogle Scholar
  25. 25.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab (Herceptin) as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.PubMedCrossRefGoogle Scholar
  26. 26.
    Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/new antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771–2777.PubMedGoogle Scholar
  27. 27.
    Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63–72.PubMedGoogle Scholar
  28. 28.
    Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/Nneu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651–3664.PubMedGoogle Scholar
  29. 29.
    Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714–2721.PubMedGoogle Scholar
  30. 30.
    Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354–363.PubMedGoogle Scholar
  31. 31.
    Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl AcadSci USA 1986;83:2934–2938.CrossRefGoogle Scholar
  32. 32.
    Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992;89:5321–5325.PubMedCrossRefGoogle Scholar
  33. 33.
    Berry D, Muss H, Thor A, et al. HER-2/neu and p53 expression versus tamoxifen. Resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471–3479.PubMedGoogle Scholar
  34. 34.
    “PathVysion” HER-2 DNA Probe Kit package instructions. Vysis Inc., Downers Grove, IL, 2000.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Robert Mass
    • 1
  1. 1.Genentech, Inc.South San FranciscoUSA

Personalised recommendations